Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Agile Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AGRX
Over the counter
8731
https://www.agiletherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Agile Therapeutics Inc
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call Transcript
- Apr 1st, 2024 9:20 pm
Q4 2023 Agile Therapeutics Inc Earnings Call
- Mar 29th, 2024 3:34 am
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
- Mar 28th, 2024 12:05 pm
Agile Therapeutics Announces Delisting from Nasdaq
- Mar 25th, 2024 8:30 pm
12 Best Biotech Penny Stocks to Invest In
- Mar 24th, 2024 7:54 pm
Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024
- Mar 21st, 2024 10:35 am
Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024
- Mar 20th, 2024 12:15 pm
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
- Mar 13th, 2024 11:31 am
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
- Feb 22nd, 2024 2:01 pm
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
- Feb 15th, 2024 9:30 pm
11 Hyper-Growth Stocks Billionaires Are Loading Up On
- Jan 25th, 2024 9:40 am
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
- Jan 23rd, 2024 2:29 pm
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
- Dec 12th, 2023 1:01 pm
Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
- Nov 22nd, 2023 2:00 pm
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q3 2023 Earnings Call Transcript
- Nov 10th, 2023 3:20 pm
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 9th, 2023 1:05 pm
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
- Oct 26th, 2023 12:05 pm
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
- Oct 4th, 2023 8:30 pm
Why Shares of Agile Therapeutics Jumped This Week
- Sep 28th, 2023 8:19 pm
Agile Therapeutics (NASDAQ: AGRX) Upgraded To “Buy” Rating By Analysts At Maxim Group
- Sep 28th, 2023 1:00 pm
Scroll